S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:CYCN

Cyclerion Therapeutics - CYCN Stock Forecast, Price & News

$0.90
-0.01 (-1.10%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
▼
$0.96
50-Day Range
$0.47
▼
$0.96
52-Week Range
$0.46
▼
$3.62
Volume
178,627 shs
Average Volume
133,515 shs
Market Capitalization
$39.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Cyclerion Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,066.5% Upside
$10.50 Price Target
Short Interest
Healthy
0.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.11) to ($1.26) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

679th out of 1,283 stocks

Pharmaceutical Preparations Industry

330th out of 615 stocks

See Top Rated MarketRank™ Stocks Here
CYCN stock logo

About Cyclerion Therapeutics (NASDAQ:CYCN) Stock

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Stock Performance

NASDAQ:CYCN traded down $0.01 on Friday, reaching $0.90. The company's stock had a trading volume of 178,627 shares, compared to its average volume of 133,515. Cyclerion Therapeutics has a 1-year low of $0.46 and a 1-year high of $3.62. The firm has a market cap of $39.11 million, a PE ratio of -0.72 and a beta of 2.31. The business's 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.88.

Cyclerion Therapeutics (NASDAQ:CYCN - Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. Cyclerion Therapeutics had a negative return on equity of 99.04% and a negative net margin of 1,115.53%. The firm had revenue of $0.71 million during the quarter, compared to analysts' expectations of $0.55 million. As a group, sell-side analysts expect that Cyclerion Therapeutics will post -1.11 EPS for the current year.

Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

July 28, 2022 | msn.com
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
July 28, 2022 | finance.yahoo.com
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
June 17, 2022 | finance.yahoo.com
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
June 10, 2022 | marketwatch.com
Cyclerion Therapeutics Posts Positive Study Data for MELAS Treatment
May 11, 2022 | finance.yahoo.com
As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year
May 4, 2022 | seekingalpha.com
Cyclerion Therapeutics reports Q1 results
May 4, 2022 | finance.yahoo.com
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
February 27, 2022 | finance.yahoo.com
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans?
February 24, 2022 | finance.yahoo.com
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
February 23, 2022 | finance.yahoo.com
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
January 27, 2022 | nasdaq.com
One Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their stake by 67% in the previous year
January 26, 2022 | finance.yahoo.com
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
November 25, 2021 | finance.yahoo.com
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year
November 9, 2021 | finance.yahoo.com
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
October 20, 2021 | finance.yahoo.com
Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside
September 17, 2021 | fool.com
Cyclerion Therapeutics Inc(CYCN)
September 8, 2021 | finance.yahoo.com
Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
July 23, 2021 | msn.com
Why Cyclerion Therapeutics Shares Are Moving Today
July 12, 2021 | finance.yahoo.com
Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares
July 9, 2021 | finance.yahoo.com
Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers
July 8, 2021 | finance.yahoo.com
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
June 8, 2021 | nasdaq.com
Tuesday 6/8 Insider Buying Report: WSC, CYCN
June 4, 2021 | nasdaq.com
Cyclerion Reaches Licensing Agreement With Akebia For Oral SGC Stimulator Praliciguat
June 4, 2021 | finance.yahoo.com
Cyclerion Therapeutics Announces $18 Million Private Placement
June 4, 2021 | finance.yahoo.com
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
See More Headlines
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Company Calendar

Last Earnings
11/09/2021
Today
8/07/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCN
CUSIP
N/A
CIK
1755237
Web
www.cyclerion.com
Phone
(857) 327-8778
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+1,066.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-51,650,000.00
Net Margins
-1,115.53%
Pretax Margin
-1,115.55%
Return on Equity
-99.04%
Return on Assets
-82.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.51
Quick Ratio
4.51

Sales & Book Value

Annual Sales
$3.94 million
Price / Sales
9.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.11 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
43,450,000
Free Float
39,451,000
Market Cap
$39.11 million
Optionable
Not Optionable
Beta
2.31

Key Executives

  • Dr. Peter M. Hecht Ph.D. (Age 58)
    CEO & Director
    Comp: $108.22k
  • Ms. Cheryl Gault (Age 42)
    Chief Operating Officer
    Comp: $513.43k
  • Dr. Andreas Busch Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $669.36k
  • Ms. Anjeza Gjino (Age 39)
    CFO & Corp. Sec.
  • Dr. Todd Milne Ph.D.
    Sr. VP of External Innovation
  • Ms. Jessica Rennekamp
    Associate Director of Corp. Communications
  • Mr. Christopher Winrow Ph.D.
    Sr. Director of Clinical Devel. & Neuroscience Program Lead
  • Ms. Jennifer Chickering Ph.D.
    Sr. Director of Clinical Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CYCN Stock - Frequently Asked Questions

Should I buy or sell Cyclerion Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclerion Therapeutics stock.
View analyst ratings for Cyclerion Therapeutics or view top-rated stocks.

What is Cyclerion Therapeutics' stock price forecast for 2022?

2 Wall Street research analysts have issued 1-year target prices for Cyclerion Therapeutics' stock. Their CYCN stock forecasts range from $7.00 to $14.00. On average, they predict Cyclerion Therapeutics' share price to reach $10.50 in the next year. This suggests a possible upside of 1,066.5% from the stock's current price.
View analysts' price targets for Cyclerion Therapeutics or view top-rated stocks among Wall Street analysts.

How has Cyclerion Therapeutics' stock performed in 2022?

Cyclerion Therapeutics' stock was trading at $1.72 on January 1st, 2022. Since then, CYCN shares have decreased by 47.7% and is now trading at $0.9001.
View the best growth stocks for 2022 here.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The business had revenue of $0.35 million for the quarter, compared to analysts' expectations of $3 million. Cyclerion Therapeutics had a negative net margin of 1,115.53% and a negative trailing twelve-month return on equity of 99.04%.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX).

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $0.90.

How much money does Cyclerion Therapeutics make?

Cyclerion Therapeutics (NASDAQ:CYCN) has a market capitalization of $39.11 million and generates $3.94 million in revenue each year. The company earns $-51,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Cyclerion Therapeutics have?

Cyclerion Therapeutics employs 32 workers across the globe.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for Cyclerion Therapeutics is www.cyclerion.com. The company can be reached via phone at (857) 327-8778 or via email at ir@cyclerion.com.

This page (NASDAQ:CYCN) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.